| scholarly article | Q13442814 |
| P50 | author | Eduardo L. Franco | Q39669535 |
| Stuart Peacock | Q56433242 | ||
| P2093 | author name string | Mel Krajden | |
| Darrel Cook | |||
| Gavin C E Stuart | |||
| Andrew J Coldman | |||
| Laurie W Smith | |||
| Dirk van Niekerk | |||
| Lovedeep Gondara | |||
| Ruth Elwood Martin | |||
| David Quinlan | |||
| Kathy Ceballos | |||
| Marette Lee | |||
| Laura Gentile | |||
| Gina Suzanne Ogilvie | |||
| P2860 | cites work | Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience | Q26745696 |
| Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 | ||
| A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial) | Q33545461 | ||
| HPV testing in primary cervical screening: a systematic review and meta-analysis | Q34255310 | ||
| Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement | Q34282601 | ||
| Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study | Q36451743 | ||
| Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study | Q37135912 | ||
| Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2 | Q37223672 | ||
| Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials | Q38160099 | ||
| Regression and Progression Predictors of CIN2 in Women Younger Than 25 Years | Q38839926 | ||
| HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer | Q39338815 | ||
| The challenges of organising cervical screening programmes in the 15 old member states of the European Union | Q39953687 | ||
| Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm | Q40299388 | ||
| Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. | Q40471804 | ||
| Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands | Q40554523 | ||
| HPV testing with cytology triage for cervical cancer screening in routine practice | Q42246425 | ||
| High-grade squamous intraepithelial lesion could be managed conservatively in women up to 25 years: results from a retrospective cohort study | Q43786609 | ||
| Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline | Q43924111 | ||
| Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance | Q45008006 | ||
| Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. | Q53028990 | ||
| Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 | ||
| Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial | Q82586477 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| cervical intraepithelial neoplasia | Q196788 | ||
| P304 | page(s) | 43-52 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial | |
| P478 | volume | 320 |
| Q64089977 | Q64089977 |
| Q91724543 | Assessing the impact of mailing self-sampling kits for human papillomavirus testing to unscreened non-responder women in Manitoba |
| Q64099366 | Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies |
| Q91026777 | Cervical cancer |
| Q96166479 | Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) |
| Q89939929 | Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study |
| Q91971979 | Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis |
| Q58564976 | Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial |
| Q63976798 | HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology |
| Q91592321 | High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
| Q90399963 | Human papillomavirus testing may detect cervical precancer better than Papanicolaou testing |
| Q92585765 | Insertional oncogenesis by HPV70 revealed by multiple genomic analyses in a clinically HPV-negative cervical cancer |
| Q90067959 | Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population |
| Q64112090 | Major clinical research advances in gynecologic cancer in 2018 |
| Q91724593 | Measuring colposcopy quality in Canada: development of population-based indicators |
| Q92080357 | Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada |
| Q92267167 | Point-of-care cervical cancer screening using deep learning-based microholography |
| Q91922934 | Prevalence and Distribution of Human Papillomavirus Genotypes Among Women in Kinshasa, The Democratic Republic of the Congo |
| Q93112009 | Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany |
| Q91027524 | Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology |
| Q64265787 | Synergistically enhanced colorimetric molecular detection using smart cup: a case for instrument-free HPV-associated cancer screening |
| Q91841593 | The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study |
| Q91480174 | The distribution and prevalence of human papillomavirus in women in mainland China |
| Q102074347 | The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia |
| Q57296920 | Too many women are dying from cervix cancer: Problems and solutions |
| Q64090005 | Top studies relevant to primary care from 2018: From PEER |
| Q99590844 | Triage human papillomavirus testing for cytology-based cervical screening in women of different ages in primary hospitals: A retrospective clinical study |
Search more.